Urologists and oncologists: Adapting to a new treatment paradigm in castration-resistant prostate cancer (CRPC)

BJU International

Volumn 110, Issue 3, 2012, Pages 328-335

  Sartor, A Oliver ^a   Fitzpatrick, John M ^b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

castration resistant prostate cancer; combined therapy; oncologist; review; urologist

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE ACETATE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CABAZITAXEL; CUSTIRSEN; DOCETAXEL; ESTROGEN; MITOXANTRONE; PACLITAXEL; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROTEIN TYROSINE KINASE INHIBITOR; RADIUM 223; SIPULEUCEL T; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; ANEMIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CASTRATION RESISTANT PROSTATE CANCER; DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EDEMA; EXTERNAL BEAM RADIOTHERAPY; FLUID RETENTION; HEART DISEASE; HUMAN; HYPOKALEMIA; LEUKOPENIA; LIVER FUNCTION TEST; MEDICAL SPECIALIST; NAIL; NEUTROPENIA; NONHUMAN; ONCOLOGIST; OVERALL SURVIVAL; PATIENT CARE; PERIPHERAL NEUROPATHY; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; UROLOGIST;

ADMINISTRATION, ORAL; ANDROGEN RECEPTOR ANTAGONISTS; ANDROSTADIENES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MALE; MEDICAL ONCOLOGY; ORCHIECTOMY; PALLIATIVE CARE; PHENYLTHIOHYDANTOIN; PHYSICIAN'S ROLE; PROFESSIONAL PRACTICE; PROSTATIC NEOPLASMS; TAXOIDS; THERAPIES, INVESTIGATIONAL; TISSUE EXTRACTS; TUMOR MARKERS, BIOLOGICAL; UROLOGY;

EID: 84863717956     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10818.x     Document Type: Review

References (46)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300
2. Ferlay J, Parkin DM, Steliarova-Foucher E,. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-81
3. American Cancer Society. Key statistics about prostate cancer. 2011. Available at:. Accessed November 2011
4. Gillitzer R, Hampel C, Thomas C, et al,. [Therapy choices of German urologists and radio-oncologists if personally diagnosed with localized prostate cancer]. Urologe A 2009; 48: 399-407
5. Jang TL, Bekelman JE, Liu Y, et al,. Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med 2010; 170: 440-50
6. Petrylak DP, Tangen CM, Hussain MH, et al,. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20 (Pubitemid 39315318)
7. Tannock IF, de Wit R, Berry WR, et al,. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12 (Pubitemid 39315317)
8. Taneja SS,. A multidisciplinary approach to the management of hormone-refractory prostate cancer. Rev Urol 2003; 5: S85-91
9. Walczak JR, Carducci MA,. Prostate cancer: a practical approach to current management of recurrent disease. Mayo Clin Proc 2007; 82: 243-9 (Pubitemid 46198485)
10. Akakura K, Akimoto S, Shimazaki J,. Pain caused by bone metastasis in endocrine-therapy-refractory prostate cancer. J Cancer Res Clin Oncol 1996; 122: 633-7 (Pubitemid 26325592)
11. Payne R,. Pain management in the patient with prostate cancer. Cancer 1993; 71: 1131-7 (Pubitemid 23049641)
12. Crawford ED,. The role of the urologist in treating patients with hormone-refractory prostate cancer. Rev Urol 2003; 5: S48-52
13. de Bono JS, Oudard S, Ozguroglu M, et al,. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-54
14. de Bono J, Logothetis CJ, Fizazi K, et al,. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005
15. Armstrong AJ, George DJ,. Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer. Prostate Cancer Prostatic Dis 2010; 13: 108-16
16. Heidenreich A, Bolla M, Joniau S, et al,. Guidelines on prostate cancer. Eur Assoc Urol 2010. Available at:. Accessed 19 January 2011
17. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology kidney cancer guidelines (Version 3.2010). 2010. Available at: NCCN website. Accessed November 2011
18. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF,. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 242-6
19. Halabi S, Vogelzang NJ, Kornblith AB, et al,. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol 2008; 26: 2544-49
20. Armstrong AJ, Garrett-Mayer ES, Yang YO, de Wit R, Tannock IF, Eisenberger M,. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 2007; 13: 6396-403 (Pubitemid 350075029)
21. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, et al,. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 2007; 25: 3965-70 (Pubitemid 47477275)
22. Lin AM, Ryan CJ, Small EJ,. Intermittent chemotherapy for metastatic hormone refractory prostate cancer. Crit Rev Oncol Hematol 2007; 61: 243-54 (Pubitemid 46329430)
23. Jevtana. [Prescribing Information]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC, 2010
24. Alter AW, Kraus LA, Bissery M-C,. In vitro activity of TXD258 in chemotherapeutic resistant tumour cell lines. Proc Am Assoc Cancer Res 2000; 41: 303. [Abstract 1923]
25. Attard G, Greystroke A, Kaye S, de Bono J,. Update on tubulin binding agents. Pathol Biol (Paris) 2006; 54: 72-84
26. Bissery MC, Bouchard H, Riou J, Vrignaud P, Combeau C, Bourzat JD,. Preclinical evaluation of TXD258, a new taxoid. Proc Am Assoc Cancer Res 2000; 41: 214. [Abstract 1364]
27. Vrignaud P, Lejeune P, Chaplin D, Lavelle F, Bissery MC,. In vivo efficacy of TXD258, a new taxoid, against human tumor xenografts. Proc Am Assoc Cancer Res 2000; 41: 214. [Abstract 1365]
28. Sanofi-Aventis. Cabazitaxel versus docetaxel both with prednisone in patients with metastatic castration resistant prostate cancer (FIRSTANA). ClinicalTrials.Gov [Internet], Bethesda, MD: National Library of Medicine (US), 2000 [cited 2011 April 25]. Available at:. Accessed November 2011
29. 2 with prednisone for the treatment of metastatic castration resistant prostate cancer (PROSELICA). ClinicalTrials.Gov [Internet], Bethesda, MD: National Library of Medicine (US), 2000 [cited 2011 April 25]. Available at:. Accessed November 2011
30. Agarwal N, Hutson TE, Vogelzang NJ, Sonpavde G,. Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer. Future Oncol 2010; 6: 665-79
31. FDA approves. Zytiga for Late-Stage Prostate Cancer [Press Release]. Bethesda, MD: US Food and Drug Administration, 2011
32. Danila DC, Morris MJ, de Bono JS, et al,. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010; 28: 1496-501
33. Cougar Biotechnology, Inc. Abiraterone acetate in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer. ClinicalTrials.Gov [Internet], Bethesda, MD: National Library of Medicine (US), 2000 [cited 2011 June 1]. Available at:. Accessed November 2011
34. Sternberg CN, Krainer M, Oh WK, et al,. The medical management of prostate cancer: a multidisciplinary team approach. BJU Int 2007; 99: 22-7 (Pubitemid 44915612)
35. Di Lorenzo G, Buonerba C, Autorino R, De Placido S, Sternberg CN,. Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs 2010; 70: 983-1000
36. Scher HI, Beer TM, Higano CS, et al,. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375: 1437-46
37. Scher HI, Fizazi K, Saad F, et al,. Effect of MDV 3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study. J Clin Oncol 2012; 30 (Suppl. 5): LBA1 [abstract]
38. Vishnu P, Tan WW,. Update on options for treatment of metastatic castration-resistant prostate cancer. Onco Targets Ther 2010; 3: 39-51
39. Small EJ, Schellhammer PF, Higano CS, et al,. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24: 3089-94 (Pubitemid 46638945)
40. Kantoff PW, Higano CS, Shore ND, et al,. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-22
41. U.S. Department of Health & Human Services. Approval letter-provenge. Food and Drug Administration website. 2010. Available at:. Accessed November 2011
42. Mulcahy N,. Discussing Provenge with patients with prostate cancer. Medscape Medical News. 2010. Available at:. Accessed November 2011
43. Nilsson S, Franzén L, Tyrrell C, et al,. Radium-223 in the treatment of metastatic hormone refractory prostate cancer (HRPC): results from a randomized, placebo-controlled, phase II study. J Clin Oncol 2007; 25: 18S. [ASCO abstract 5071]
44. Parker C, Heinrich D, O'Sullivan JM, et al,. Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. J Clin Oncol 2012; 30 (Suppl. 5): 8 [abstract]
45. Chi KN, Hotte SJ, Yu E, et al,. Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone vs docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2009; 27: 15S. [Abstract 5012]
46. de Bono JS, Scher HI, Montgomery BR, et al,. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14: 6302-9